Free Trial
→ From the man who predicted 2008 crash… (From Porter & Company) (Ad)tc pixel Free DRUG Stock Alerts

Bright Minds Biosciences (DRUG) Financials

Bright Minds Biosciences logo
$86.55 +1.05 (+1.23%)
Closing price 05/11/2026 04:00 PM Eastern
Extended Trading
$85.25 -1.30 (-1.50%)
As of 04:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Bright Minds Biosciences

Annual Income Statements for Bright Minds Biosciences

This table shows Bright Minds Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.36 -6.84 -11 -5.45 -2.07 -8.78
Consolidated Net Income / (Loss)		 -0.36 -6.84 -11 -5.45 -2.07 -8.78
Net Income / (Loss) Continuing Operations		 -0.36 -6.84 -11 -5.45 -2.07 -8.78
Total Pre-Tax Income 		-0.36 -6.84 -11 -5.45 -2.07 -8.78
Total Operating Income		 -0.36 -6.96 -11 -5.46 -2.09 -10
Total Gross Profit		 -0.08 -0.68 -0.55 -1.18 -0.77 -0.89
Total Revenue		 -0.08 -0.58 -0.47 -0.32 -0.41 -0.53
Operating Revenue		 -0.08 -0.58 -0.47 -0.32 -0.41 -0.53
Total Cost of Revenue		 0.00 0.11 0.07 0.85 0.37 0.36
Operating Cost of Revenue		 0.00 0.11 0.07 0.85 0.37 0.36
Total Operating Expenses		 0.28 6.28 10 4.28 1.32 9.12
Selling, General & Admin Expense		 0.00 0.16 0.35 0.21 0.20 0.56
Marketing Expense		 0.01 0.67 0.40 0.09 0.03 0.31
Research & Development Expense		 0.27 4.99 8.86 3.69 0.87 7.96
Other Operating Expenses / (Income)		 0.00 0.46 0.74 0.29 0.22 0.29
Total Other Income / (Expense), net		 0.00 0.12 0.01 0.01 0.02 1.23
Interest & Investment Income		 - - - 0.00 0.02 1.09
Other Income / (Expense), net		 0.00 0.12 0.01 0.01 -0.01 0.14
Weighted Average Basic Shares Outstanding		 3.61M 1.79M -4.41 3.72M 4.31M 7.64M
Weighted Average Diluted Shares Outstanding		 3.61M 1.79M 2.47M 3.72M 4.31M 7.64M
Weighted Average Basic & Diluted Shares Outstanding		 3.61M 1.79M 4.94M 3.72M 4.31M 6.88M

Quarterly Income Statements for Bright Minds Biosciences

No quarterly income statements for Bright Minds Biosciences are available.

Annual Cash Flow Statements for Bright Minds Biosciences

This table details how cash moves in and out of Bright Minds Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Change in Cash & Equivalents		 0.54 15 -6.10 -4.26 -0.77 55
Net Cash From Operating Activities		 0.55 -5.79 -9.88 -5.19 -1.37 -6.24
Net Cash From Continuing Operating Activities		 0.55 -5.92 -9.90 -5.26 -1.37 -5.60
Net Income / (Loss) Continuing Operations		 -0.36 -6.84 -11 -5.45 -2.07 -8.78
Consolidated Net Income / (Loss)		 -0.36 -6.84 -11 -5.45 -2.07 -8.78
Depreciation Expense		 0.00 0.00 0.00 0.05 0.05 0.06
Non-Cash Adjustments To Reconcile Net Income		 0.83 0.52 0.45 0.99 0.47 2.06
Changes in Operating Assets and Liabilities, net		 0.08 0.40 0.53 -0.85 0.18 1.07
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash From Financing Activities		 0.00 21 3.78 1.62 0.60 61
Net Cash From Continuing Financing Activities		 0.00 22 2.74 1.00 0.60 62
Repayment of Debt		 - 0.00 -0.01 -0.06 -0.07 -0.07
Issuance of Common Equity		 - - - 0.90 0.67 59
Other Financing Activities, net		 - 22 2.93 0.19 0.00 2.82

Quarterly Cash Flow Statements for Bright Minds Biosciences

No quarterly cash flow statements for Bright Minds Biosciences are available.

Annual Balance Sheets for Bright Minds Biosciences

This table presents Bright Minds Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Total Assets		 0.66 16 8.79 5.08 4.52 61
Total Current Assets		 0.66 16 8.69 5.03 4.43 61
Cash & Equivalents		 0.60 16 8.46 4.99 4.23 60
Prepaid Expenses		 0.06 0.13 0.12 0.02 0.22 0.99
Current Deferred & Refundable Income Taxes		 0.00 0.09 0.08 0.03 0.04 0.15
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.10 0.05 0.09 0.08
Other Noncurrent Operating Assets		 - 0.00 0.10 0.05 0.09 0.08
Total Liabilities & Shareholders' Equity		 0.66 16 8.79 5.08 4.52 61
Total Liabilities		 0.11 0.50 1.12 0.21 0.42 1.71
Total Current Liabilities		 0.11 0.50 1.07 0.21 0.53 2.34
Accounts Payable		 0.11 0.50 1.02 0.15 0.33 1.62
Other Current Liabilities		 - 0.00 0.05 0.05 0.06 0.06
Total Noncurrent Liabilities		 0.00 0.00 0.05 0.00 0.03 0.03
Other Noncurrent Operating Liabilities		 - - - - - 0.03
Total Equity & Noncontrolling Interests		 0.44 15 7.67 4.87 4.10 59
Total Preferred & Common Equity		 0.55 15 7.67 4.87 4.10 59
Total Common Equity		 0.44 15 7.67 4.87 4.10 59
Common Stock		 0.74 21 23 25 26 88
Retained Earnings		 -0.42 -7.28 -18 -23 -25 -33
Other Equity Adjustments		 0.12 1.24 1.80 3.13 3.30 3.86

Quarterly Balance Sheets for Bright Minds Biosciences

No quarterly balance sheets for Bright Minds Biosciences are available.

Annual Metrics And Ratios for Bright Minds Biosciences

This table displays calculated financial ratios and metrics derived from Bright Minds Biosciences' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 9/30/2020 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
DEI Shares Outstanding		 0.00 11,834,361.00 17,592,359.00 4,463,837.00 - 7,635,789.00
DEI Adjusted Shares Outstanding		 0.00 2,366,872.00 3,518,472.00 4,463,837.00 - 7,635,789.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -2.89 -3.09 -1.22 - -1.15
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% -596.93% 17.91% 31.61% -25.37% -30.95%
EBITDA Growth		 0.00% -1,791.66% -58.92% 50.37% 61.94% -380.79%
EBIT Growth		 0.00% -1,791.66% -58.99% 49.90% 61.32% -370.97%
NOPAT Growth		 0.00% -1,825.36% -56.33% 49.84% 61.52% -379.01%
Net Income Growth		 0.00% -1,791.67% -59.14% 49.95% 61.93% -323.42%
EPS Growth		 0.00% -1,791.67% -59.14% 0.00% 67.11% 0.00%
Operating Cash Flow Growth		 0.00% -1,160.22% -70.77% 47.47% 63.12% -355.74%
Free Cash Flow Firm Growth		 0.00% 0.00% -54.30% 37.92% 66.86% -331.36%
Invested Capital Growth		 0.00% -432.72% -160.25% 84.98% 3.57% -866.89%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.09% 100.00% 99.67% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 98.94% 88.95%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -82.42% -86.70% -94.62% -86.86% -46.23% -27.87%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -82.42% -86.84% -94.73% -86.86% -46.23% -27.87%
Return on Equity Simple (ROE_SIMPLE)		 -65.87% -44.51% -141.95% 0.00% -50.61% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.25 -4.87 -7.62 -3.82 -1.47 -7.01
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -22.05% -24.41% -27.19% -24.30% -13.20% -5.59%
Return On Investment Capital (ROIC_SIMPLE)		 - - -98.68% -78.36% -35.55% -11.89%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -0.36 -6.84 -11 -5.45 -2.10 -9.87
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.36 -6.84 -11 -5.39 -2.05 -9.82
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 1.90 1.15 1.27 4.66
Price to Tangible Book Value (P/TBV)		 0.00 0.00 1.90 1.15 1.27 4.66
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.01 0.00 0.01 0.00
Long-Term Debt to Equity		 0.00 0.00 0.01 0.00 0.01 0.00
Financial Leverage		 -1.12 -1.02 -1.04 -1.07 -1.02 -1.01
Leverage Ratio		 1.51 1.05 1.07 1.11 1.07 1.03
Compound Leverage Factor		 1.51 1.05 1.07 1.11 1.06 0.92
Debt to Total Capital		 0.00% 0.00% 0.68% 0.00% 0.71% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.68% 0.00% 0.71% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.17% 99.32% 100.00% 99.29% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.01 0.00
Net Debt to EBITDA		 0.00 0.00 0.77 0.00 2.05 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.01 0.00
Debt to NOPAT		 0.00 0.00 -0.01 0.00 -0.02 0.00
Net Debt to NOPAT		 0.00 0.00 1.10 0.00 2.87 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.01 0.00 -0.02 0.00
Altman Z-Score		 0.00 0.00 1.88 7.40 -0.98 96.32
Noncontrolling Interest Sharing Ratio		 0.00% -0.17% -0.12% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 5.82 31.38 8.11 24.26 11.32 25.92
Quick Ratio		 5.30 30.94 7.92 24.03 10.82 25.49
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -4.64 -7.16 -4.45 -1.47 -6.57
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.35 0.09 1.46 1.50 0.37
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 1,045.00 3,851.80 250.86 242.54 995.97
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.05 -0.28 -0.74 -0.11 -0.11 -0.49
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.23 -0.45 0.63 0.00 -0.44
Enterprise Value (EV)		 0.00 0.00 6.15 0.64 1.02 215
Market Capitalization		 0.00 0.00 15 5.63 5.22 274
Book Value per Share		 $0.12 $8.56 $0.65 $0.28 $0.92 $13.02
Tangible Book Value per Share		 $0.12 $8.56 $0.65 $0.28 $0.92 $13.02
Total Capital		 0.44 15 7.72 4.87 4.13 59
Total Debt		 0.00 0.00 0.05 0.00 0.03 0.00
Total Long-Term Debt		 0.00 0.00 0.05 0.00 0.03 0.00
Net Debt		 -0.60 -16 -8.40 -4.99 -4.20 -60
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.05 -0.28 -0.84 -0.16 -0.19 -1.33
Debt-free Net Working Capital (DFNWC)		 0.55 15 7.62 4.83 4.04 58
Net Working Capital (NWC)		 0.55 15 7.62 4.83 4.04 58
Net Nonoperating Expense (NNE)		 0.11 1.97 3.27 1.63 0.61 1.78
Net Nonoperating Obligations (NNO)		 -0.49 -16 -8.40 -4.99 -4.20 -59
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.05 0.05 0.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.80) ($6.05) ($1.98) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 2.37M 3.52M 4.46M 0.00 7.64M
Adjusted Diluted Earnings per Share		 $0.00 ($4.80) ($6.05) ($1.98) ($0.48) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 2.37M 3.52M 4.46M 4.52M 7.64M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($4.80) ($6.05) ($1.98) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.79M 2.47M 7.44M 8.62M 6.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.25 -4.87 -7.62 -3.82 -1.47 -7.01
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -3.36% -1.74% -0.37% 0.00% 0.00%

Quarterly Metrics And Ratios for Bright Minds Biosciences

No quarterly metrics and ratios for Bright Minds Biosciences are available.


Financials Breakdown Chart

Bright Minds Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Bright Minds Biosciences' fiscal year ends in September. Their fiscal year 2025 ended on September 30, 2025.

Bright Minds Biosciences' net income appears to be on an upward trend, with a most recent value of -$8.78 million in 2025, rising from -$361.48 thousand in 2020. The previous period was -$2.07 million in 2024. See where experts think Bright Minds Biosciences is headed by visiting Bright Minds Biosciences' forecast page.

Bright Minds Biosciences' total operating income in 2025 was -$10.01 million, based on the following breakdown:
  • Total Gross Profit: -$887.96 thousand
  • Total Operating Expenses: $9.12 million

Over the last 5 years, Bright Minds Biosciences' total revenue changed from -$82.64 thousand in 2020 to -$530.88 thousand in 2025, a change of 542.4%.

Bright Minds Biosciences' total liabilities were at $1.71 million at the end of 2025, a 305.7% increase from 2024, and a 1,402.6% increase since 2020.

In the past 5 years, Bright Minds Biosciences' cash and equivalents has ranged from $601.94 thousand in 2020 to $59.53 million in 2025, and is currently $59.53 million as of their latest financial filing in 2025.

Over the last 5 years, Bright Minds Biosciences' book value per share changed from 0.12 in 2020 to 13.02 in 2025, a change of 10,626.2%.


Related Companies

Financial statements for NASDAQ:DRUG last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Read this or regret it forever
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Your book attached
Veteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...
Profits Run | Sponsoredtc pixel
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...
Brownstone Research | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel
Iran War Update: Trump’s Hand-Written Letter Reveals What Comes Next
Jim Rickards has uncovered what he believes is Trump's economic plan, with a key trigger date of May 15. The F...
Paradigm Press | Sponsoredtc pixel